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Background: To decide whether a person with certain characteristics should be given any kind of
intervention to prevent a cardiovascular event, it would be helpful to classify subjects in low, medium
and high risk categories. The study evaluated which well known cerebrovascular and cardiovascular
correlates, in particular fibrinogen level and ECG characteristics, are able to predict the occurrence of
stroke in men of the general population using data from three European cohorts participating in
EUROSTROKE.
Methods: EUROSTROKE is a collaborative project among ongoing European population based cohort
studies and designed as a prospective nested case-control study. For each stroke case two controls
were sampled. Strokes were classified according to MONICA criteria or reviewed by a panel of four
neurologists. Complete data were available of 698 men (219 stroke events) from cohorts in Cardiff (84
cases/200 controls), Kuopio (74/148) and Rotterdam (61/131). Multivariable logistic regression
modeling was used to evaluate which information from history, physical examination (for example,
blood pressure), blood lipids, and fibrinogen and ECG measurements independently contributed to the
prediction of stroke. The area under receiver operating characteristic curve (ROC area) was used to
estimate the predictive ability of models.
Results: Independent predictors from medical history and physical examination were age, stroke his-
tory, medically treated hypertension, smoking, diabetes mellitus and diastolic blood pressure. The ROC
area of this model was 0.69. After validating and transforming this model to an easy applicable rule,
40% of all future stroke cases could be predicted. Adding pulse rate, body mass index, blood lipids,
fibrinogen level and ECG parameters did not improve the classification of subjects in low, medium and
high risk. Results were similar when fibrinogen was dichotomised at the upper tertile or quintile.
Conclusion: In the general male population the future occurrence of stroke may be predicted using
easy obtainable information from medical history and physical examination. Measurement of pulse
rate, body mass index, blood lipids, fibrinogen level and ECG characteristics do not contribute to
the risk stratification of stroke and have no value in the screening for stroke in the general male
population.
Coronary heart disease and cerebrovascular disease arestill major causes of morbidity, disability and death inmost industrialised countries. Over the years several
modifiable cardiovascular risk factors have been identified
that are associated with an increased risk of coronary heart
disease or cerebrovascular disease. This has offered ways for
treatment and prevention. For example, intervention studies
showed that treatment of mild to moderate hypertension or
lowering serum total cholesterol by drug treatment in subjects
with raised levels, reduces the risk of coronary heart disease
and cerebrovascular disease. However, it has been repeatedly
shown that subjects at the highest absolute risk of future
cardiovascular events benefit more from these interventions
than those at low or intermediate risk.1–5
Practising physicians regularly have to decide whether a
particular patient with certain cardiovascular characteristics
should be put on (drug) treatment. For this decision the
potential benefits and hazards of the intervention should be
carefully weighted. To provide “tailored care”, a number of
guidelines for practising physicians have been issued in which
the start of treatment in an individual patient is related to the
individuals absolute risk of future coronary heart disease and
cerebrovascular disease.6 7 An established approach for estima-
tion of individual risks (risk stratification) is the use of risk
functions or prediction rules, in which the probability of
occurrence of disease is estimated as a combined function of
the levels of various cardiovascular risk factors. Several of such
risk function are present to predict coronary heart disease,8 9
stroke10–12 and all cause mortality.13 None of those available
function for stroke have focused on ECG based myocardial
infarction or fibrinogen.
Increased levels of fibrinogen have consistently been
associated with increased risk of coronary heart disease and
stroke.14–16 In addition, fibrinogen has been shown to be related
to presence and extent of atherosclerosis.17 18 Based on these
findings, measurement of fibrinogen has been implicated as a
tool to help distinguishing subjects at high cardiovascular risk
from those with lower risk.19 Signs on an ECG of a previous
myocardial infarction is an easily obtainable measurement for
indication of an individual risk of cardiovascular disease. Mis-
classification of previous myocardial infarction is much less
using an ECG based diagnosis compared with questionnaire
based diagnosis, and thus prognostic value of the first is in
general increased.20
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This study evaluated which well known correlates of stroke
contribute to the prediction of stroke occurrence in men of the
general population using data from three European cohorts
participating in EUROSTROKE. In particular, we determined
the added value of fibrinogen level and electrocardiogram
(ECG) characteristics to these established correlates for the
classification of subjects in low, medium and high risk catego-
ries. We aimed to define an easily applicable scoring or predic-
tion rule that can be used by physicians as a screening tool to
early estimate the risk of future stroke in men.
METHODS
EUROSTROKE is a collaborative study among 10 European
research centres to investigate (1) the variation in incidence of
fatal and non-fatal ischaemic and haemorrhagic stroke among
populations in different European countries; (2) whether the
observed differences in stroke incidence across countries can be
explained by differences in prevalence of established cardiovas-
cular risk factors; (3) the relative importance of smoking, some
selected dietary factors (potassium intake, alcohol consump-
tion), haemostatic disturbances (fibrinogen) and comorbidity
(rheumatic heart disease, atrial fibrillation) as determinants of
the occurrence of ischaemic and haemorrhagic stroke. The
EUROSTROKE database is drawn from 10 ongoing European
population-based prospective follow up studies (cohorts) and is
designed as a case-control study nested within these 10 ongoing
cohort studies. Because EUROSTROKE is based on ongoing
studies, information on cardiovascular risk factors in each of the
participating centres was already collected before the formal
start of the EUROSTROKE project. An exhaustive attempt was
made to further harmonise the collected information to make
comparison across studies possible. At each moment that a case
occurred the corresponding cohort was sampled for two control
subjects. Controls were matched on day of baseline examination
only. At present data, from three cohort studies (Finland, the
Netherlands and United Kingdom) 698 male subjects, 219
stroke events and 479 controls, were used in the present analy-
ses. The mean follow up time of the 698 patients was 7.3 years
(range 0.9–20.9 years). The rationale and design of EURO-
STROKE have been described in detail elsewhere.21 The EURO-
STROKE project formally started on 1 January 1994.
Outcome (stroke) definition: EUROSTROKE case review
board
A case reviewing panel consisting of four neurologists
classified all stroke events occurring in EUROSTROKE based
on the information that was obtainable such as patients’ his-
tory, results from lumbar puncture, computed tomography or
magnetic resonance imaging, findings from necropsy report,
and final codes from existing and operating registries such as
for example the FINMONICA registry. Stroke was defined as a
clinical event of rapid onset consisting of neurological deficit
lasting more than 24 hours unless death supervenes, or if it
lasts less than 24 hours, an appropriate lesion to explain the
deficit is seen in a brain image. The event could not be directly
caused by trauma to the brain, tumour, or infection. Based on
the information present, the neurologist classified the event
into first and recurrent stroke, and into subarachnoid
haemorrhage, intracranial haemorrhage, intracerebral infarc-
tion, or unspecified stroke. Cerebral infarction was classified
according to internationally accepted criteria.22 23 In addition,
the certainty of the diagnosis was assessed in definite,
probable, possible and no stroke. The present analysis is
restricted to definite and probable strokes. A stroke was
considered to have occurred when (1) the event had led to a
hospitalisation and the hospital discharge record indicated a
diagnosis of a new stroke. The clinical diagnosis was based on
signs and symptoms, and neuroimaging investigations during
hospital stay (definite stroke); or (2) in case of no hospitalisa-
tion, signs and symptoms associated with the event obtained
from the general practitioner’s records were highly suggestive
of a stroke according to the neurologists (probable stroke) or
(3) in case of out hospital death, when the general practitioner
reported that the cause of death was a cerebrovascular
accident and a cardiac cause was judged by the general prac-
titioner to be highly unlikely (probable stroke).
Finland
The Finnish contribution to EUROSTROKE comes from the
Kuopio Ischaemic Heart Disease Risk Factor study, which is a
population-based prospective cohort study comprised of an
age stratified random sample of 2682 men aged 42, 48, 54 and
60 years. The baseline examination was performed between
1984 and 1989.24 Fatal and non-fatal stroke cases were
collected through the national mortality statistics and the
FINMONICA stroke registries. Stroke was defined according
to FINMONICA criteria and definitions.25 Presently, case
ascertainment revealed 74 (definite or probable) stroke cases.
Altogether 148 control subjects were randomly drawn from
the cohort (sampling fraction 1:17.6).
The Netherlands
The Dutch contribution to EUROSTROKE comes from the
Rotterdam Study, which is a population-based prospective fol-
low up study among 7983 subjects (3130 men; 4853 women),
aged 55 years or over, living in the suburb of Ommoord in Rot-
terdam, the Netherlands.26 Baseline data were collected from
March 1990 to July 1993. In the Rotterdam Study, information
on incident fatal and non-fatal events is obtained from the
general practitioners (GPs) working in the study district of
Ommoord as has been detailed elsewhere.27 Fatal and
non-fatal stroke cases were collected through a GP based reg-
istry. In short, the GPs involved report all possible cases of
stroke to the Rotterdam research centre. All suspected
cerebrovascular events reported by the GPs were submitted for
review to the EUROSTROKE case review board. Presently, 61
events among men were classified as definite or probable
strokes and a total of 131 control subjects were randomly
drawn from the male cohort (sampling fraction 1:23.4).
United Kingdom
The British contribution to EUROSTROKE comes from the
Caerphilly Heart Disease study in Wales, United Kingdom, in
which 2512 men, aged 45 to 59 years are participating.28
Baseline examinations took place from 1979 to 1983. Follow up
examinations were performed from 1984 to 1988 (phase II) and
from 1989 to 1993 (phase III). Stroke events were registered
through national mortality statistics, hospital discharge records,
self report and family report. Of the registered events, additional
information on signs and symptoms, neuroimaging, necropsy
and a copy of the discharge records were collected when avail-
able. When complete, stroke cases were submitted for review to
the EUROSTROKE case review board. At present, 100 stroke
events had been submitted for review and a total of 200 controls
subjects were drawn (sampling fraction = 1:12.1). Eighty four
of the 100 reviewed cases were classified as definite/probable
stroke by the EUROSTROKE review board.
Potential predictors
Although exhaustive attempts were made to harmonise the
collected information, measurements could not be further
standardised beyond the attempts done in each individual
study. In each centre, baseline information on medical history
was obtained by questionnaire. Smoking behaviour was
categorised into current, former or never, and alcohol
consumption into current drinkers and non-current drinkers
(former and never). History of hypertension was considered
present if the patient used antihypertensive drugs. Presence of
diabetes mellitus was generally based on direct questioning
“Do you suffer from diabetes mellitus” although in the
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Rotterdam study diabetes mellitus was considered present
when subjects used blood sugar lowering drugs. Information
on personal and familial history of stroke and myocardial inf-
arction (MI), was based on direct questioning (for example,
“Did you ever suffer from a stroke?”). Presence of angina pec-
toris was based on either the cardiovascular Rose question-
naire or direct questioning. Height and weight were measured
and body mass index (kg/m2) calculated.
In general, systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were measured at baseline twice (at one occa-
sion) in sitting position. In Cardiff, only one blood pressure
measurement was performed. A fasting (apart from Rotter-
dam) blood sample was taken at baseline for determination of
serum lipids (total and HDL cholesterol). Fibrinogen level was
measured at baseline according to the Von Clauss method in
Kuopio, according to the nephelometric method in Cardiff and
in Rotterdam fibrinogen levels were derived from the clotting
curve of the prothrombin time assay using Thromborel S as
reagent on an Automated Coagulation Laboratory. The latter
method correlates well with the Von Clauss method. In all
centres an ECG was made at baseline of which three
characteristics were evaluated: left ventricular hypertrophy
(LVH), presence of MI and arrythmia (defined as presence of
atrial fibrillation, atrial flutter or sinus arrythmia). In Kuopio
and Cardiff LVH was assessed according to the Minnesota
classification system (codes 3.1, 3.3, 3.4).29 In Rotterdam, an
automated diagnostic classification system of the Modular
Electrocardiogram Analysis System (MEANS) was used in
which LVH diagnosis was assessed on the parameters voltage,
shape and repolarisation, as detailed elsewhere,30 31 and MI as
described by de Brunye and coworkers.32
Data analysis
Firstly, within each country, the association (odds ratio (OR)
and 95% confidence intervals (95% CI)) between the
occurrence of stroke and each potential predictor was quanti-
fied using univariable logistic regression analyses in order to
evaluate whether there were major differences between the
three countries. Subsequently, if a test for homogeneity
showed no major heterogeneity (p value >0.10), the three ORs
were pooled using the Mantel-Haenszel method to estimate
an overall (pooled) estimate of the association of each predic-
tor with the outcome. Continuous variables were initially ana-
lysed without categorisation but various cut off values and
transformations (square root, log) were evaluated as well.33 34
Then, multivariable logistic regression modelling was
applied to assess the independent contribution of variables in
the prediction of stroke. Models were constructed in
accordance to the chronology in which predictors are to be
documented in clinical practice. Hence, we first included all
variables from patient history into an overall “history model”.
Model reduction was performed by excluding variables with p
values >0.10. The reduced “history model” was consecutively
extended with body mass index, blood pressure parameters,
pulse rate, blood lipids, fibrinogen level and ECG characteris-
tics to evaluate their added value in the prediction of stroke. Of
each model, the reliability (goodness of fit) was quantified
using the Hosmer and Lemeshow test35 and their ability to
discriminate between patients with and without stroke using
the area under the receiver operating characteristic curve
(ROC area).36 The ROC area is a suitable parameter to summa-
rise the discriminative or predictive value and can range from
0.5 (no discrimination, like a coin flip) to 1.0 (perfect
discrimination). Differences in predictive value between
different (extended) models was estimated by comparison of
ROC areas taking into account the correlation between the
models as they were based on the same subjects.37 38
Besides evaluation of the added value of various tests such
as fibrinogen level and ECG characteristics, we also aimed to
define one final model that predicts stroke best. To adjust for
overfitting—that is, to adjust for too optimistic estimates of
the odds ratio (or regression coefficient) of the predictors in
the final model—bootstrapping techniques were used as a
method of model validation.34 39 Subsequently, to obtain an
easy applicable prediction rule, the adjusted regression coeffi-
cients of the validated model were multiplied by a factor 10
and rounded to the nearest integer.
In multivariable analyses 235 subjects had missing values for
one or more predictors. The average number of missings per
predictor was 4%, ranging from 0.2% to a maximum of 21%.
Missing data are seldom at random. It has been shown that
deleting subjects with a missing value on one of the predictors
included in the multivariable model (so called complete case
analyses) commonly leads to biased results and surely to a loss
of power.34 40 41 To decrease bias and to increase statistical
efficiency, it is better to impute these missings rather than doing
a complete case analyses.34 40 41 Accordingly, we imputed per
country (that is, before pooling) our missing data using the
expectation maximisation method available in SPSS (version
9.0) software. Such imputation is based on the correlation
between each variable with missing values and all other
variables as estimated from the (463) complete subjects.
Furthermore, as the different countries showed different distri-
butions of various predictors such as age, blood lipids and ECG
characteristics, we repeated the analyses after equalising the
variances and symmetrising the distributions of the predictors.
Two methods were used: (1) per country, dividing each predic-
tor by its corresponding standard deviation and (2) per country,
transforming each predictor to a standard normal distribution
score (Z score)—that is, (value−mean)/standard deviation.
These analyses also yielded similar results such that only the
results from the untransformed predictors is presented.
RESULTS
Table 1 shows the distribution of the potential predictors per
country and in the pooled data. Differences across countries
were present for age, smoking, history of MI, hypertension
and angina pectoris, and ECG characteristics. However, for all
predictors the odds ratios were reasonably homogenous
between the different countries: all tests for homogeneity had
a p value >0.10. Table 2 shows the stroke characteristics per
country and in the pooled dataset. Of the 219 stroke events,
187 (85%) were first strokes.
Table 3 shows the results of the univariable analyses of the
pooled data. When fibrinogen level was dichotomised at the
upper tertile or at the upper quintile, it was also significantly
associated with stroke with odds ratios of 2.1 (95% CI: 1.4 to
3.0) and 1.9 (95% CI: 1.3 to 2.7), respectively.
The overall history model (that is, first 10 variables of table
3) had a ROC area of 0.66. The reduced history model (model
1, table 4) had the same ROC area. Further exclusions or other
combinations of predictors significantly decreased the ROC
area. Body mass index, pulse rate and blood lipids did not have
added value to model 1. When adding blood pressure
measurements to model 1, DBP was, and SBP was not signifi-
cant. Hence, we retained only DBP (model 2, table 4). None of
the various definitions of hypertension, such as, SBP>160 mm
Key points
• In the general male population, occurrence of stroke may
be predicted using easy obtainable information from medi-
cal history and physical examination.
• Age, stroke history, medically treated hypertension,
smoking, diabetes mellitus and diastolic blood pressure are
independent predictors of stroke.
• Pulse rate, body mass index, blood lipids, fibrinogen level
and ECG characteristics have no added value in the
screening for stroke in the general male population.
i32 Moons, Bots, Salonen, et al
www.jech.com
Hg, DBP>90 mm Hg or current blood pressure lowering drug
use; SBP>140 mm Hg, DBP>95 mm Hg or current blood
pressure lowering drug use; SBP-DBP, yielded a higher predic-
tive accuracy than model 2. Addition of the three ECG charac-
teristics to model 2 marginally increased the ROC area from
0.69 to 0.70. Of these three, only the presence of MI was inde-
pendently associated with stroke (OR=2.5; 95% CI:1.4 to 5.0).
Fibrinogen when added to model 2 was marginally associated
with stroke (model 3, table 4). Excluding smoking from table
3, the ROC area remained 0.70 and the ORs of the other pre-
dictors were essentially unchanged. Also, when fibrinogen
level was included as a dichotomous term, the performance of
model 3 was not improved. Combined addition of fibrinogen
level and the three ECG characteristics to model 2, yielded a
ROC area of 0.70. The fit of all models was good: Hosmer and
Lemeshow tests were far from significant (p values >0.50).
As fibrinogen level nor ECG variables showed added value,
model 2 was defined as the final model that was validated
using bootstrapping (table 5). The validated model was then
transformed to an easy applicable scoring rule: 0.3 × age + 19
× history of stroke + 8 × diabetes + 5 × current smoking + 3
× history of hypertension + 0.2 × diastolic blood pressure (last
column table 5). Such scoring rule can be considered as one
overall predictor or screening test (including several indi-
vidual predictor variables). The score can be considered as its
(test) result and was estimated for each subject by assigning
the points for each predictor present and adding these points.
For instance, a subject of 60 years, who has a history of stroke
and diabetes, does not smoke, has no history of hypertension
and with a diastolic blood pressure of 80, receives a score of 61
(18 + 19 + 8 + 0 + 0 + 16). In our data, the score ranged from
27 to 72 (mean 39) and the ROC area of the rule was 0.68 (95%
CI: 0.63 to 0.73).
To obtain an estimate of the absolute incidence of stroke
across categories of the score in the total cohort, all control
subjects were given a weight that was the inverse of the sam-
pling fraction from their corresponding cohort (that is, 17.6
for the controls of the Finland cohort, 23.4 for the Dutch
Table 1 General characteristics of the participating centres and the overall study population
Characteristic Cardiff, UK (n=284) Kuopio, FIN (n=222) Rotterdam, NL (n=192) All (n=698)
Case/control 84/200 74/148 61/131 219/479
Age (y) 58 (6) 55 (4) 72 (9) 61 (9)
Current alcohol use (%) 90.3 81.0 75.8 86.5
Current smoking (%) 47.2 27.9 30.8 36.6
Body mass index (kg/m2) 26.6 (3.6) 27.0 (3.4) 25.9 (3.3) 26.5 (3.5)
Body mass index >25 kg/m2 (%) 66 70 58 65
Family history of stroke (%) 30.6 19.8 24.5 25.5
Family history of MI (%) 35.6 49.5 36.5 40.3
Diabetes mellitus (%) 4.2 6.3 7.9 5.9
History of stroke (%) 3.2 5.4 8.1 5.2
History of MI (%) 3.9 11.7 16.5 9.9
History of hypertension (%) 18.3 22.5 14.6 18.6
Angina pectoris (%) 13.7 32.4 13.6 19.7
Pulse rate (beats/minute) 60 (18) 44 (13) 69 (18) 57 (19)
Systolic pressure (mm Hg) 146 (22) 133 (18) 145 (23) 141 (22)
Diastolic pressure (mm Hg) 86 (13) 89 (10) 77 (13) 85 (13)
Total cholesterol (mmol/l) 5.8 (1.2) 6.1 (1.2) 6.3 (1.2) 6.0 (1.2)
HDL cholesterol (mmol/l) 1.05 (0.33) 1.26 (0.28) 1.20 (0.31) 1.17 (0.32)
Fibrinogen level (g/l) 4.04 (0.95) 3.20 (0.62) 2.84 (0.71) 3.56 (0.95)
MI on ECG (%) 5.3 4.1 17.9 8.2
Arrythmia on ECG (%) 3.2 8.1 12.5 7.3
LVH on ECG (%) 3.5 4.0 6.8 4.2
Values are unadjusted proportions or means with standard deviations in parentheses.
UK, United Kingdom; FIN, Finland; NL, The Netherlands; MI, myocardial infarction; ECG, electrocardiogram; LVH, left ventricular hypertrophy.
Table 2 Stroke characteristics of the participating
centres and the overall study population
Characteristic
Cardiff, UK
(n=284)
Kuopio, FIN
(n=222)
Rotterdam,
NL (n=192)
All
(n=698)
Total stroke 84 (38) 74 (34) 61 (28) 219
Fatal 24 14 10 48
Non-fatal 60 60 51 171
Haemorrhagic 11 15 5 31
Ischaemic 57 54 42 153
Unspecified 16 5 14 35
First stroke 74 (40) 66 (35) 47 (25) 187
Fatal 20 11 7 38
Non-fatal 54 55 40 149
Haemorrhagic 10 14 5 29
Ischaemic 52 47 32 131
Unspecified 12 5 10 27
Values are absolute numbers and percentages between parentheses.
UK, United Kingdom; FIN, Finland; NL, The Netherlands.
Table 3 Association of each potential predictor with
stroke occurrence in the overall study population (n=698)
Potential predictor
Stroke
present
(n=219)
Stroke
absent
(n=479)
Odds ratio
(95% CI)
Age (per year)* 62 60 1.1 (1.0 to 1.1)
Current smoking (%) 43.3 33.5 1.7 (1.2 to 2.3)
Current alcohol use (%) 86.5 86.5 1.1 (0.6 to 1.8)
Diabetes mellitus (%) 10.6 3.8 2.8 (1.5 to 5.4)
History of stroke (%) 13.4 1.5 10.0 (4.5 to 25.3)
History of MI (%) 12.9 8.4 1.5 (0.9 to 2.6)
History of hypertension (%) 26.9 14.8 2.1 (1.4 to 3.1)
Angina pectoris (%) 19.7 19.6 0.9 (0.6 to 1.4)
Family history of stroke (%) 24.8 21.1 1.2 (0.7 to 2.0)
Family history of MI (%) 41.0 40.0 1.1 (0.8 to 1.5)
Pulse rate (per beat/minute)* 59 56 1.0 (1.0 to 1.0)
Body mass index (per kg/m2)* 26.6 26.4 1.0 (0.9 to 1.1)
Systolic BP (per 10 mm Hg)* 146 139 1.2 (1.1 to 1.3)
Diastolic BP (per 10 mm Hg)* 87 84 1.3 (1.1 to 1.4)
Total cholesterol (per mmol/l)* 6.0 6.0 1.0 (0.9 to 1.2)
HDL level (per mmol/l)* 1.15 1.18 0.6 (0.3 to 1.1)
Fibrinogen level (per g/l)* 3.78 3.46 1.5 (1.2 to 1.9)
MI on ECG (%) 14.0 5.8 2.7 (1.5 to 5.1)
Arrythmia on ECG (%) 7.1 7.8 1.0 (0.5 to 1.8)
LVH on ECG (%) 6.4 3.7 1.8 (0.8 to 3.9)
The odds ratios are adjusted for age (except the odds ratio for age).
MI, myocardial infarction; ECG, electrocardiogram; LVH, left
ventricular hypertrophy.
*Values are means.
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controls and 12.1 for the British controls).42 43 Hence, a new
dataset was created that included all 219 cases and the
weighted control group resembling the entire cohort. Table 6
shows the incidence of subjects across selected score
categories. From this table one can directly obtain the predic-
tive value for presence or absence of stroke per score category
(reading horizontally). For example, of all 232 subjects with a
score >50, 14.2% (n=33) developed a stroke while this was
only 1% (n=9) in the 762 subjects with a score <30. Reading
the table vertically provides estimates of the sensitivity and
specificity at different thresholds. For example, 1316
(640+444+232) subjects (8%+5%+3% = 16% of total)
received a score >41. Of these, 86 (33+20+33) indeed devel-
oped a stroke, correctly predicting 39% of all future stroke
patients (that is, the sensitivity or true positive rate) and 1230
did not develop a stroke, 16% of all “non-stroke” subjects pre-
dicted as future stroke cases (that is, the 1− specificity or false
positive rate); a specificity of 84%. Using a threshold of >46,
the sensitivity was 24% with only 8% false positives
(specificity=92%).
DISCUSSION
With the aim to provide more tailored care in the future, this
study evaluated which patient information may predict the
presence of future stroke occurrence in men of the general
population (aged 40 to 85) using data from three European
countries participating in EUROSTROKE. We have shown that
easy obtainable patient information can reasonably predict
the occurrence of stroke within seven years. Using these
parameters as a simple screening instrument facilitates the
early prediction of about 40% of all future stroke cases (sensi-
tivity) with only about 15% false positive predictions (subjects
incorrectly predicted as stroke cases). Pulse rate, body mass
index, blood lipids, nor fibrinogen level and ECG characteris-
tics show added value to the simple, non-invasive characteris-
tics in the risk stratification.
These results are in agreement with a large number of
studies reporting that higher age, smoking, diabetes mellitus,
previous stroke, hypertension history and increased diastolic
blood pressure are associated with an increased risk of
stroke.44–47 The fact, however, that a risk factor is significantly
associated with stroke does not automatically imply that this
factor is of use for (early) identification of high or low risk
subjects. This is very evident from our analyses, which indeed
showed that additional to the medical history plus blood pres-
sure, well known correlates such as pulse rate, body mass
index, fibrinogen level and ECG characteristics do not
(considerably) add to the prediction of future stroke events.
Hence, we do not recommend using these latter measure-
ments as screening tools in the general population to detect
early stroke events. As fibrinogen level and ECG characteris-
tics did marginally contribute to the prediction of stroke, it
would be interesting, for example, to evaluate whether the
(marginal) benefit from measuring fibrinogen levels in all
aged, diabetic and smoking men with a history of stroke, out-
weigh the corresponding measurement costs and patient bur-
den. Further research seems necessary in this area.
The major advantage of a pooled analyses or meta-analyses
is to quantify associations with much more precision as com-
pared with individual studies. However, to appreciate the
results of our pooled analyses some aspects need to be
discussed. Firstly, because of the EUROSTROKE design, the
classification of stroke was not done uniformly. The same
applies to the definition of the ECG characteristics.
Nevertheless, the associations of the investigated factors did
not show major differences across the different countries such
that a pooled analyses was indicated. Moreover, in daily prac-
tice similar differences between countries and medical
Table 4 Independent predictors of stroke (odds ratio with 95% CI between parentheses)
Predictor Model 1 Patient history
Model 2 Patient history
+ blood pressure
Model 3 Patient history
+ blood pressure
+ fibrinogen
Age (per year) 1.02 (1.00 to 1.04) 1.03 (1.01 to 1.05) 1.03 (1.01 to 1.05)
History of stroke 7.68 (3.21 to 18.40) 7.67 (3.19 to 18.41) 7.46 (3.10 to 17.92)
Diabetes 2.2 1 (1.11 to 4.43) 2.38 (1.18 to 4.78) 2.38 (1.18 to 4.80)
Current smoking 1.67 (1.18 to 2.36) 1.69 (1.19 to 2.39) 1.57 (1.10 to 2.24)
History of hypertension 1.58 (1.03 to 2.43) 1.43 (0.92 to 2.20) 1.41 (0.91 to 2.18)
Diastolic blood pressure (per mm Hg) – 1.02 (1.01 to 1.04) 1.02 (1.01 to 1.04)
Fibrinogen level (per g/l) – – 1.16 (0.98 to 1.38)
ROC area (95% CI) 0.66 (0.62 to 0.70) 0.69 (0.64 to 0.73) 0.70 (0.65 to 0.75)
ROC area = area under receiver operating characteristic curve.
Table 5 Odds ratio, regression coefficient and score
of each predictor from Model 2 (table 4) after validation
Predictor Odds ratio
Regression
coefficient* Score†
Age (per year) 1.03 0.03 0.3
History of stroke 6.36 1.85 19
Diabetes 2.26 0.80 8
Current smoking 1.60 0.47 5
History of hypertension 1.39 0.33 3
Diastolic blood pressure
(per mm Hg)
1.02 0.02 0.2
The constant of the model after bootstrapping was −4.64.
*Regression coeffcient = ln (odds ratio); †the score per predictor is
obtained by multiplying the regression coefficient by 10, and then
rounded to nearest integer.
Table 6 Estimated distribution of patients with and
without stroke in the original cohort (of the three
countries combined) according to the risk score of
model 2 (table 4 and 5)
Risk
score Total*
Stroke incidence
(%)† Stroke‡ No stroke§
<30 762 1.0 9 (4) 753 (9)
30–35 2712 1.4 38 (18) 2674 (33)
36–40 3519 2.4 86 (39) 3433 (42)
41–45 640 5.2 33 (15) 607 (8)
46–50 444 4.5 20 (9) 424 (5)
>50 232 14.2 33 (15) 199 (3)
Total 8309 219 (100) 8090 (100)
Values represent absolute number of patients and percentages of the
column total between parentheses (except for stroke incidence).
*Total number of patients per score category; †actual (observed)
stroke incidence per score category; ‡number of subjects with stroke
per score category; §number of subjects without a stroke per score
category.
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practices will be present and risk estimates should be
sufficiently robust to overcome this heterogeneity. Secondly,
the frequency of arrythmia on the ECG was dominated by
sinus arrythmia and the prevalence of atrial fibrillation was
low. We could therefore not adequately study the predictive
value of atrial fibrillation. Thirdly, differences in distributions
of continuous predictors across centres may also have biased
the findings. When the analyses were repeated using distribu-
tion independent techniques we found similar results.
Fourthly, the inception of the Rotterdam study was about 10
years later (in 1990) than the other two studies. Diagnostic
procedures to detect stroke (for example, computed tomogra-
phy and magentic resonance imaging) had been introduced
during the mid-eighties. This introduction might have
improved the detection of minor stroke cases and a better
subclassification of detected stroke cases (for example, better
distinction between haemorraghic and non-haemorraghic
strokes). The latter could not affect the present results because
our outcome was the presence or absence of any stroke. But, in
the first years of the Cardiff and Kuopio study, a number of
minor stroke cases could have been missed. As all sampled
controls were extensively screened on the absence of any
stroke (minor and major), the missed stroke cases could not
have affected the specificity but only the sensitivity of our pre-
diction model. We believe, however, that this bias is small as
the problem could only occur in the first years of the Kuopio
and Cardiff study. Fifthly, because of the case-control design of
this study the odds ratios (regression coefficients) of the pre-
dictors are correctly estimated whereas a baseline risk of
stroke (or the intercept of a prediction model) could not be
directly estimated. Therefore, we reported in table 6 a
transformed scoring rule that does not use the intercept (as it
is equal for each subject anyway) but still enables classifi-
cation of subjects according to their absolute risk of stroke.
Such scoring rule is easier to apply in practice. To estimate the
absolute risk for future subjects in the population at hand, one
can use the regression coefficients in table 5. If the incidence
in the population at hand is different from ours (2.6%), the
intercept in table 5 should be adjusted using standard
techniques.48 49 Finally, although we used bootstrapping
techniques to validate the scoring rule external validation
studies are necessary before its application to practice.
We suggested to use an arbitrary threshold of 41 in the risk
score above which patients are classified as future cases of
stroke which yielded a sensitivity of about 40% and specificity
of 84%. It should be noted that these estimates apply to a
prognostic setting and should not be confused with (usually
much higher) estimates obtained from a diagnostic setting.
Furthermore, with our choice of threshold we assumed that
16% false positive predictions would be acceptable merely
because the consequences of this misclassification (that is,
closer attention by the physician) do not cause much harm.
Moreover, as these false predictions do have higher risk scores
and probably worse prognosis than those with low risk scores,
the former will benefit from the closer attention anyway.
Nevertheless, using table 5 one could choose other thresholds
in the risk score leading to other percentages of misclassifica-
tions. Proper definition of thresholds requires information
about acceptable “costs” related to misclassifications and was
beyond the scope of this paper. This also requires further
research.
In conclusion, in the general male population the occur-
rence of stroke may be predicted early using six simple char-
acteristics. Pulse rate, body mass index, blood lipids, fibrino-
gen level and ECG characteristics do not seem valuable in the
screening for future stroke cases. Additional research is neces-
sary to validate the proposed scoring rule in new subjects and
to evaluate its cost effectiveness.
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